Drugs · acquisition-cost intelligence
Tosymra
sumatriptan· ingredient sumatriptan· SUMATRIPTAN 10 mg/.1mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$108.15
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other sumatriptan products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Sumatriptan | $0.34058 | −$107.81 |
| Treximet | $11.67 | −$96.48 |
| Sumatriptan | $15.06 | −$93.09 |
| sumatriptan | $16.06 | −$92.09 |
| sumatriptan | $17.57 | −$90.58 |
| sumatriptan | $69.54 | −$38.62 |
| IMITREX | $72.50 | −$35.66 |
| Zembrace SymTouch | $384.03 | +$275.87 |
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.